ReviewCurrent allergy and asthma reports2026
Hypersensitivity Reactions to Biologics: Advances in Diagnosis and Management.
Review in Current allergy and asthma reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe landscape of biologic therapeutics has expanded to include therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. As the use of these therapies expands, hypersensitivity reactions (HSRs) can limit the use of preferred treatments. This review examines advances in the diagnosis and management of these adverse events, including applications of precision medicine and AllergoOncology. RECENT
findingsRecent studies have identified hereditary alpha tryptasemia (HαT) and female sex as potential risk factors for biologic-induced anaphylaxis. Excipients such as PEG and polysorbates are increasingly recognized as potential triggers of first-exposure reactions. The basophil activation test (BAT) has emerged as a complementary tool for evaluating IgE-mediated hypersensitivity and differentiating it from cytokine release syndrome (CRS). Recent approaches to rapid drug desensitization (RDD) include one-bag protocols, same-day desensitization, and omalizumab as an adjunct in selected patients. The approach to biologic hypersensitivity is increasingly guided by reaction phenotype, diagnostic evaluation, and individualized management.
Indexed as
Identifiers
42804013What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.